Humacyte Inc (NASDAQ: HUMA): Do Not Miss The Gain Train

Humacyte Inc (HUMA) concluded trading on Thursday at a closing price of $1.57, with 3.84 million shares of worth about $6.03 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -71.71% during that period and on April 10, 2025 the price saw a gain of about 2.61%. Currently the company’s common shares owned by public are about 130.03M shares, out of which, 125.85M shares are available for trading.

Stock saw a price change of 8.28% in past 5 days and over the past one month there was a price change of -47.49%. Year-to-date (YTD), HUMA shares are showing a performance of -68.91% which decreased to -48.36% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.15 but also hit the highest price of $9.97 during that period. The average intraday trading volume for Humacyte Inc shares is 3.41 million. The stock is currently trading -28.83% below its 20-day simple moving average (SMA20), while that difference is down -48.77% for SMA50 and it goes to -68.43% lower than SMA200.

Humacyte Inc (NASDAQ: HUMA) currently have 130.03M outstanding shares and institutions hold larger chunk of about 27.76% of that.

The stock has a current market capitalization of $243.53M and its 3Y-monthly beta is at 1.64. It has posted earnings per share of -$1.26 in the same period. It has Quick Ratio of 2.40. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HUMA, volatility over the week remained 17.61% while standing at 12.61% over the month.

Stock’s fiscal year EPS is expected to rise by 39.23% while it is estimated to increase by 56.90% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 20, 2024 offering a Buy rating for the stock and assigned a target price range of between $12 and $15 to it. Coverage by H.C. Wainwright stated Humacyte Inc (HUMA) stock as a Buy in their note to investors on December 11, 2023, suggesting a price target of $6 for the stock. On August 14, 2023, Piper Sandler Upgrade their recommendations, while on June 22, 2023, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $6. Stock get an Underweight rating from Piper Sandler on May 16, 2022.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.